Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.

Recent news :

May 2024 – Affilogic takes part in the NAVIPP Project : Since beginning of 2024, Affilogic is a member of the NAVIPP project. The consortium will implement a strategic, multi gear R&D and clinical roadmap for the identification, optimisation, preclinical and clinical investigation of broad-spectrum antivirals against pathogens with epidemic or pandemic potential.

Jan 2024 – Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®: Iconovo AB and Affilogic today announce that Iconovo will present positive results from a feasibility study with a Nanofitin®-based biologic drug against respiratory virus using ICOone®. The study results will be presented at Respiratory Drug Delivery (RDD®) 2024, which takes place in Tucson, Arizona, on May 5-9, 2024.

Around the world

BiotechShowcase 2025

BiotechShowcase 2025

Affilogic will attend next BiotechShowcase in San-Francisco – USA
Jan 13-15, 2025

Visit the event website

I4ID Lyon 2024

I4ID Lyon 2024

Affilogic presenting at 8th I4ID in Lyon – France
Nov 27-28, 2024

Visit the event website

BIO EUROPE 2024

BIO EUROPE 2024

Affilogic will attend next BIO EUROPE in Stockholm – Sweden
Nov 4-6, 2024

Visit the event website

Nanofitins

Our Programs

NanoVector